Article in Molecular cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
Arvin C DarDepartment of Oncological Sciences, The Tisch Cancer Institute, Mount Sinai Centre for Therapeutic Discovery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pharmaceutical Sciences, The Tisch Cancer Institute, Mount Sinai Centre for Therapeutic Discovery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: arvin.dar@mssm.edu.
Donita C BradyDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: bradyd@pennmedicine.upenn.edu.
Cancer Research Institute · USIcahn School of Medicine at Mount Sinai · US
Funding
Molecular and Cellular Mechanisms of Copper-Dependent Nutrient Signaling and MetabolismR35GM124749 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Donita C Brady · 2017 to 2026
$4.6M
Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSRR01CA227636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Arvin Dar · 2018 to 2026
$4.0M
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICSR01CA256480 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DAR, ARVIN, GUCCIONE, ERNESTO · 2021 to 2025
$3.3M
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal CancerR01CA258736 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAR, ARVIN · 2021 to 2025
$3.2M
Unlocking the Chemical Space of Cancer-Associated PerturbationsR01CA280833 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BRADY, DONITA C, BURSLEM, GEORGE · 2022 to 2025
$2.2M
A Cytochrome P450 Therapeutic Space for TauopathiesR56AG066712 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAGAN, ROSS LEIGH, DAR, ARVIN · 2021 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
RASopathy mutations open new insights into the mechanism of BRAF activation. · full record | OpenQuestion